1040 related articles for article (PubMed ID: 16203784)
21. Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer.
Lin SY; Chang HH; Lai YH; Lin CH; Chen MH; Chang GC; Tsai MF; Chen JJ
PLoS One; 2015; 10(5):e0123305. PubMed ID: 25955608
[TBL] [Abstract][Full Text] [Related]
22. 3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
Hehlgans S; Lange I; Eke I; Cordes N
Radiother Oncol; 2009 Sep; 92(3):371-8. PubMed ID: 19729215
[TBL] [Abstract][Full Text] [Related]
23. SRC signaling is crucial in the growth of synovial sarcoma cells.
Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
[TBL] [Abstract][Full Text] [Related]
24. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Shi Q; Hjelmeland AB; Keir ST; Song L; Wickman S; Jackson D; Ohmori O; Bigner DD; Friedman HS; Rich JN
Mol Carcinog; 2007 Jun; 46(6):488-96. PubMed ID: 17219439
[TBL] [Abstract][Full Text] [Related]
25. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
[TBL] [Abstract][Full Text] [Related]
26. Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-transformed cells.
Brábek J; Constancio SS; Siesser PF; Shin NY; Pozzi A; Hanks SK
Mol Cancer Res; 2005 Jun; 3(6):307-15. PubMed ID: 15972849
[TBL] [Abstract][Full Text] [Related]
27. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
28. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049
[TBL] [Abstract][Full Text] [Related]
29. Anchorage-independent phosphorylation of p130(Cas) protects lung adenocarcinoma cells from anoikis.
Wei L; Yang Y; Zhang X; Yu Q
J Cell Biochem; 2002; 87(4):439-49. PubMed ID: 12397603
[TBL] [Abstract][Full Text] [Related]
30. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma.
Mack PC; Gandara DR; Bowen C; Edelman MJ; Paglieroni T; Schnier JB; Gelmann EP; Gumerlock PH
Clin Cancer Res; 1999 Sep; 5(9):2596-604. PubMed ID: 10499638
[TBL] [Abstract][Full Text] [Related]
31. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
32. Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1.
Mukhopadhyay NK; Gilchrist D; Gordon GJ; Chen CJ; Bueno R; Lu ML; Salgia R; Sugarbaker DJ; Jaklitsch MT
Ann Thorac Surg; 2004 Aug; 78(2):450-7. PubMed ID: 15276495
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
34. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Song L; Turkson J; Karras JG; Jove R; Haura EB
Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Src activation with cardiotoxin III blocks migration and invasion of MDA-MB-231 cells.
Tsai PC; Chu CL; Chiu CC; Chang LS; Lin SR
Toxicon; 2013 Nov; 74():56-67. PubMed ID: 23933586
[TBL] [Abstract][Full Text] [Related]
38. The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells.
Serrels A; McLeod K; Canel M; Kinnaird A; Graham K; Frame MC; Brunton VG
Int J Cancer; 2012 Jul; 131(2):287-97. PubMed ID: 21823119
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Buettner R; Mesa T; Vultur A; Lee F; Jove R
Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
[TBL] [Abstract][Full Text] [Related]
40. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.
Leung EL; Tam IY; Tin VP; Chua DT; Sihoe AD; Cheng LC; Ho JC; Chung LP; Wong MP
Mol Cancer Res; 2009 Jun; 7(6):923-32. PubMed ID: 19491201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]